drugset / Trial / NCT02871427
Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
NaSingle-groupOpen-labelTreatment
Summary
This study seeks to evaluate the long-term safety and effectiveness of nelotanserin for the treatment of visual hallucinations (VHs) and Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with Lewy body dementia (LBD).
Timeline
- Start
- 2016-10-20
- Primary completion
- 2019-01-17
- Completion
- 2019-01-17
Outcome
Outcome not reported
Stopped: “Changes to the overall development program for the study medication”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nelotanserin | Small molecule | 20 mg | Oral |
| Subject | Nelotanserin | Small molecule | 40 mg | Oral |
| Subject | Nelotanserin | Small molecule | 60 mg | Oral |
| Subject | Nelotanserin | Small molecule | 80 mg | Oral |